Drug intelligence / Profile preview

LEO 27847

Development stage: Phase 1
Lead developer: LEO Pharma
Modality: Small Molecules
Administration: Oral

Overview

LEO 27847 is an investigational small molecule drug developed by LEO Pharma for the oral treatment of secondary hyperparathyroidism (sHPT), particularly in patients with chronic kidney disease. sHPT is characterized by excessive secretion of parathyroid hormone (PTH) due to low calcium levels, often as a complication of chronic renal failure. LEO 27847 belongs to the class of calcimimetics, which act on calcium-sensing receptors in tissues such as the parathyroid gland to reduce PTH secretion and help prevent bone weakening associated with sHPT. Development for this compound has been discontinued[1][2][3].

Targets

CaSR (Extracellular calcium-sensing receptor)

Beyond the preview

Go deeper on LEO 27847.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEO 27847.

Explore the full profile